Severe glomerulonephritis complicated by coagulopathy: treatment with anticoaguland and immunosuppresive drugs.
Serial determinations, using plasma fibrinogen gel chromatography as well as standard methodology, demonstrated that six children with severe glomerulonephritis, characterized on renal biopsy by glomerular necrosis and crescent formation, had persistent evidence of intravascular coagulation. Based on these observations, therapy with anticoagulants and azathicoagulants and azathioprine was instituted for one year; treatment with anticoagulants was continued for a second year. Anticoagulant therapy was initiated with heparin, followed by oral anticoagulation with phenindione and dipyridamole. In contrast to our earlier experience with similar patients, each of the present patients improved. Urinalyses returned to normal and glomerular filtration rates to near normal values in all patients at the end of the treatment period and have remained so for up to 3.9 years since treatment has been completed. Post-treatment biopsies showed remarkable improvement, with virtually no glomerulosclerosis even in patients who had had a high incidence of glomerular crescents before treatment. It is suggested that the therapeutic regimen favorably influenced the natural history of disease and that plasma fibrinogen chromatographic findings may be helpful in selecting patients likely to benefit from the use of anticoagulant therapy.
D000208:Acute Disease; D000293:Adolescent; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology* / Q000652:urine; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism / Q000627:therapeutic use; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005921:Glomerulonephritis / Q000150:complications* / Q000188:drug therapy / Q000652:urine; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male
D000925:Anticoagulants; D005338:Fibrin Fibrinogen Degradation Products; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D006493:Heparin; D001379:Azathioprine